Skip to main content
. 2016 Mar 1;18(5):491–499. doi: 10.1111/dom.12639

Figure 2.

DOM-12639-FIG-0002-c

Liraglutide exposure and body weight loss in men and women. Liraglutide exposure expressed as model‐derived area under the curve (AUC) at steady state versus body weight change from baseline (A) for men and women in Trials 1–3 combined (covariate adjusted values); (B) for men and women at the extremes of exposure. Body weight data are mean values (with 95% confidence intervals). Horizontal bars with circles/squares/triangles represent median and 90% exposure ranges from each dose level (A), or from men and women at the extremes of exposure (B). Sigmoidal curved lines represent covariate‐adjusted model‐based estimates for defined populations. (A) Exposure expressed as six quantiles of AUC values (plus placebo). (B) Exposure and weight change for the placebo‐ or liraglutide‐treated heaviest men and lightest women, as well as the overall cohort mean in Trial 1. Trial 1, SCALE Obesity and Prediabetes; Trial 2, SCALE Diabetes; Trial 3, the phase II trial.